| 34.89 2.31 (7.09%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 43.45 |
1-year : | 47.42 |
| Resists | First : | 37.2 |
Second : | 40.59 |
| Pivot price | 33.55 |
|||
| Supports | First : | 31.7 |
Second : | 26.38 |
| MAs | MA(5) : | 33.09 |
MA(20) : | 34.05  |
| MA(100) : | 49.9 |
MA(250) : | 55.41 |
|
| MACD | MACD : | -2 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 27.8 |
D(3) : | 19.3 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 79.65 | Low : | 28.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRTA ] has closed below upper band by 16.2%. Bollinger Bands are 57% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.97 - 35.22 | 35.22 - 35.41 |
| Low: | 31.53 - 31.77 | 31.77 - 31.96 |
| Close: | 34.55 - 34.95 | 34.95 - 35.27 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Sun, 03 Dec 2023
Prothena (NASDAQ:PRTA) shareholder returns have been strong ... - Yahoo Finance
Wed, 01 Nov 2023
Is Prothena Corporation PLC (PRTA) a Smart Choice in Biotechnology Wednesday? - InvestorsObserver
Fri, 27 Oct 2023
Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk - Simply Wall St
Mon, 16 Oct 2023
Prothena Reportedly Prepares for Potential Sale -October 16, 2023 ... - Marketscreener.com
Thu, 31 Aug 2023
Prothena to Participate in Upcoming Healthcare Conferences - Business Wire
Tue, 11 Jul 2023
Prothena to Present New Data from Alzheimer's Disease Programs ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.959e+007 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 4,390 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1175e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -52 % |
| Operating Margin | 12.1 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -14.4 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 1123.4 |
| Sales Per Share | 3.20409e+008 |
| EBITDA (p.s.) | -1.85591e+008 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 19.9 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.33 |
| Dividend | 0 |
| Forward Dividend | 6.5e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|